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Abstract
Chondroblastoma (CB) is a rare benign tumour (<1% of all bone tumours) involving
epiphyseal long bones (male : female 1.5 : 1). During development, and in the postnatal
period, IHh/PTHrP and FGF signalling molecules control the space and timing of
chondrocyte differentiation. Considering the close relationship of CB with the growth plate
(age and location), the expression of proteins involved in epiphyseal growth regulation
was studied. Twelve cases of CB were retrieved. Immunohistochemistry was performed
using antibodies against fibroblast growth factor-2 (FGF-2), fibroblast growth factor
receptor-1 (FGFR-1), FGFR-3, bcl-2, p21, parathyroid hormone-related peptide (PTHrP),
and parathyroid hormone-related peptide receptor (PTHR1). Three observers evaluated
haematoxylin and eosin (H&E)-stained and immunostained slides independently. Semi-
quantitative estimation of the matrix, the type of matrix, and immunostaining was
performed. Cellular and matrix-rich areas were evaluated separately. Diverse amounts and
types of matrix were present in different tumours, as well as within individual tumours.
Signalling molecules were expressed in 50–100% of the cases. Higher levels of expression
were found in cellular areas than in matrix-rich areas, especially for PTHR1, bcl-2, and
FGFR-3. CB is an unusual entity affecting specific sites, showing that both IHh/PTHrP
and FGF signalling are active. Higher expression was found in cellular than in matrix-
rich areas, as in the proliferating/pre-hypertrophic growth plate zone in comparison with
the hypertrophic/calcifying zone. Previous studies have shown the same molecules to be
expressed with a similar pattern in chondrosarcomas. The sum of the evaluated features
indicates that CB is a neoplasm originating from a mesenchymal cell committed towards
chondrogenesis via active growth plate signalling pathways. Copyright  2003 John Wiley
& Sons, Ltd.
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Introduction
Chondroblastoma is an uncommon benign bone neo-
plasm that typically involves the epiphyses of long
bones in skeletally immature individuals. It accounts
for less than 1% of all bone tumours, with a defi-
nite male sex predominance (1.5 : 1) [1,2]. The lesion
is composed of a proliferation of immature cartilage
cells (chondroblasts) set within a distinctive and het-
erogeneous matrix. The latter can be osteoid, fibrous,
or so-called ‘chondroid’, or even, but more focally and
rarely, as clearly identifiable mature cartilage.
During development of the epiphyseal growth plate,
there is proliferation, differentiation, and matura-
tion of chondrocytes through a number of strati-
fied physiological zones (reserve, proliferating, pre-
hypertrophic/maturing, and hypertrophic) in orderly,
longitudinal columns with terminal ossification and
closure of the growth plate following puberty. Regula-
tion of these physiological changes probably involves
a number of signalling pathways including a delicate
paracrine feedback loop involving both IHh/PTHrP
and FGF signalling. In the embryonic growth plate,
chondrocytes in transition from the proliferating to
the hypertrophic zone secrete IHh, which has to dif-
fuse to the lateral perichondrium, where its receptor,
Patched (ptc), is expressed [3]. Subsequently, PTHrP
is expressed (via a still incompletely understood mech-
anism) in the apical perichondrium and diffuses to
its receptor PTHR1, whose expression is limited to
late proliferating chondrocytes. Via up-regulation of
bcl-2, further chondrocyte differentiation is inhibited,
resulting in suppression of IHh secretion, which neg-
atively influences the feedback loop. Postnatally, the
IHh/PTHrP feedback loop is restricted to the carti-
lage growth plate itself. In fact, IHh diffuses to ptc,
located in the hypertrophic zone, up-regulating PTHrP
expression, which through binding with its receptor,
also located in the hypertrophic zone, will up-regulate
bcl-2 expression [3]. Thus, PTHrP fluxes influence and
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control the pace of chondrocyte differentiation with
subsequent regulation of longitudinal bone growth
[3,4].
The FGF signalling pathway is another important
factor, probably acting in concert with the pathway
described above. FGF-2 is a potent mitogen for chon-
drocytes and stimulates extracellular matrix produc-
tion. In contrast, FGFR-3, expressed in the proliferat-
ing zone of the growth plate, can be bound by FGF-18,
resulting in inhibition of chondrocyte proliferation via
phosphorylation of STAT-1 with subsequent nuclear
expression of p21WAF1/CIP1, which is an inhibitor of
the cell cycle [5–7]. This probably serves to inhibit
bone growth as well as chondrocyte proliferation. IHh
is repressed by FGFR-3, probably by modulation of
the bone morphogenetic protein (BMP4) and ptc [8],
which would promote the progression of chondrocytes
to the hypertrophic zone, restricting longitudinal bone
growth. While recent work on conventional central and
secondary peripheral chondrosarcomas has identified
putative disturbances within this signalling pathway
[4], very little is known about the possible aetiological
role that disruption of these feedback loops may play
in chondroblastoma tumourigenesis and subsequent
intra-tumoural differentiation pathways. In order to
evaluate possible disturbances within these signalling
pathways, we investigated the immunohistochemical
expression profiles of proteins known to be involved
in normal growth regulation: fibroblast growth factor-2
(FGF-2), fibroblast growth factor receptor-1 (FGFR-
1), FGFR-3, bcl-2, p21, parathyroid hormone-related
peptide (PTHrP), and parathyroid hormone-related
peptide receptor (PTHR1). The results were compared
with the expression pattern in the normal growth plate




Formalin-fixed, formic acid-decalcified (pH 2.1; 24 h),
and paraffin wax-embedded archival tumour tissue was
available for routine staining and immunohistochemi-
cal analysis of 12 cases of chondroblastoma. All cases
were retrieved from the surgical pathology files of the
Leiden University Medical Centre, in accordance with
standard laboratory practice, and examined following
haematoxylin and eosin (H&E) staining to confirm the
previous diagnosis. Appropriate clinical information
was obtained from case notes and radiological reports.
All patient material was used in a coded manner,
for which code breaking and correlation with clini-
cal data were only possible for physicians involved in
treatment of the patients. The research was conducted
following all local ethical guidelines.
Immunohistochemistry
Four-micrometre-thick sections were mounted on 3-
aminopropylethoxysilane (APES) (Sigma, St Louis,
MO, USA) and glutaraldehyde-coated slides and dried
overnight at 37 ◦C. Details of the antibodies used for
immunohistochemical analysis are listed in Table 1.
Dr J Walters of Oxford Brookes University, Oxford,
UK kindly provided the FGFR-1 antibody. Immuno-
histochemical reactions were performed as described
earlier [9]. According to our experience, the decalcifi-
cation method used with formic acid has no significant
influence on antibody reactivity, as shown in earlier
studies with these antibodies [4]. Following dewax-
ing, rehydration, and blocking of endogenous peroxi-
dase, antigen retrieval was performed in all cases. For
FGFR-3 and PTHrP, slides for immunohistochemical
analyses were pretreated with a 0.1% trypsin solu-
tion in 0.05% calcium chloride, pH 7.4. For FGF-2,
FGFR-1, PTHR1, p21, and bcl-2 (microwave antigen
retrieval), sections for immunohistochemical analyses
were pretreated with a 0.01 M citrate buffer, pH 6.0.
Following pre-treatment, all sections were incubated
overnight with the primary antibodies. Biotin-labelled
rabbit anti-mouse immunoglobulins and a biotinylated
HRP–streptavidin complex (DAKO, Glostrup, Den-
mark) were applied. Visualization was carried out in
a diaminobenzidine solution (Sigma, St Louis, MO,
Table 1. Details of the antibodies used for immunohistochemical analysis
Antigen Source Clone Staining Positive control Internal control Dilution Antigen retrieval
FGF-2 Transduction
Laboratories
Clone 6 MC Nuclear Tonsil, skin Osteoblasts, blood vessel
walls, mast cells
1 : 125 MWO/10 min
FGFR-1 Gift∗ MC Cyt Skin Osteoblasts, blood vessel
walls
1 : 2000 MWO/10 min
FGFR-3 Sigma PC Cyt Skin Striated muscle, blood vessel
walls, connective tissue,
osteoclasts
1 : 2000 Trypsin
p21 Calbiochem MC Nuclear Colon None 1 : 2000 MWO/10 min
PTHrP Oncogene PC Cyt Skin None 1 : 25 Trypsin
PTHR1- Babco PC Cyt/nuclear Skin Blood vessel walls,
osteoblasts
1 : 500 MWO/10 min
bcl-2 Boehringer Clone 124 Cyt Tonsil Osteoblasts, lymphocytes 1 : 100 MWO/10 min
∗ See under the materials and methods section and Acknowledgements. PC = polyclonal; MC = monoclonal; Cyt = cytoplasmic staining;
nuclear = nuclear staining; FGF-2 = fibroblast growth factor-2; FGFR-1 = fibroblast growth factor receptor-1; FGFR-3 = fibroblast growth factor
receptor-3; PTHrP = parathyroid hormone-related peptide; PTHR1 = parathyroid hormone-related peptide receptor; MWO = microwave oven.
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USA), with the addition of 0.01 M imidazole for
FGFR-1. The slides were counterstained with haema-
toxylin. Appropriate positive control slides were pre-
pared according to the specificity of each antibody.
Internal positive controls were present in most of the
histological slides, allowing evaluation of the antigenic
property of tissue after decalcification. As negative
controls, slides were incubated with mouse or rabbit
IgG of a corresponding (iso-) type and concentration
instead of primary specific antibodies.
Morphological evaluation
Slides were reviewed and scored by three of us inde-
pendently (SR, JVMGB, and PCWH). Chondroblas-
toma diagnosis was confirmed and a search for an
associated aneurysmal bone cyst (ABC) was per-
formed. The percentage of the extension of the matrix-
rich areas was estimated semi-quantitatively (0 =
0–10%; 1 = 11–25%; 2 = 26–50%, 3 = 51–75%;
and 4 = 76–100%). In addition, the contribution of
the different types of matrix (osteoid, chondroid, and
fibrous) was estimated as a percentage. According to
the literature [10], we considered as ‘chondroid’ deep
pink matrix, less fibrillar than osteoid, and with more
obvious perilacunar cartilage cell-like spaces.
Evaluation and criteria used for scoring
Only cases of chondroblastoma with an appropriate
internal control for the various antibodies used were
included in this study. All 12 cases retrieved from
the archives met these criteria. All the tumours were
scored using the summation of intensity of signal (pos-
sible range: 0 = no expression; 1 = weak expression;
2 = moderate expression; 3 = strong expression) and
the number of positive cells (% tumour cells: 0 =
0%; 1 = 1–25%; 2 = 26–50%, 3 = 51–75%; 4 =
76–100%) as described previously by us [4,11,12]
and others [13]. The cellular and matrix-rich areas
were evaluated separately. Three different observers
(SR, JVMGB, and PCWH) scored the immunostained
slides separately. The three authors reviewed dis-
crepant cases together, reaching a consensus agree-
ment. The above-mentioned scoring system empha-
sizing both the staining intensity and the percentage
of cells is highly reproducible in our hands and has
also been used in previous studies on decalcified bone
tumour specimens [4]. The mean sum score (MSS)
was calculated using the SPSS 10 software package.
Particular attention was paid to giant cells, both
osteoclast-like and multinucleated tumour cells. Given
the heterogeneous location in the same tumours, the
intensity of signal and the distribution of staining
were also evaluated on a six-tiered scale: negative,
weak focal, moderate focal, weak diffuse, moder-
ate diffuse, and strong diffuse. Striking differences
from the reactivity of the normal nearby osteoclasts
were also recorded. The cellular region demonstrat-
ing immunopositivity was noted (nuclear, cytoplasmic,
and membranous). The sum score of intensity and per-
centage was calculated and the mean value reported for
both cellular and matrix-rich areas. Cut-offs as applied
in a previously published study [4] were used to sum-
marize the results obtained in terms of numbers of
positive and negative cases. In general, a sum score
higher than 3 was considered positive, with the excep-
tion of p21 and FGFR1, for which a sum score above
0 was considered positive.
Statistical analysis
In order to evaluate correlations between matrix for-
mation and signalling pathways and the interactions of
different molecules, statistical analysis using Fisher’s




The male/female ratio was 3 : 1 and the age at presen-
tation ranged between 11 and 30 years (mean 17 years
and median 15.5 years). Four cases each involved the
epiphysis of the humerus and tibia (33.3% and 33.3%),
three the epiphyses of the femur (25%), and one the os
ischium (8.3%). The relevant clinicopathological data
are summarized in Table 2.
Morphological evaluation
All the retrieved cases fulfilled the diagnostic criteria
for chondroblastoma. One case (case 10) showed the
presence of both fibrous matrix and an aneurysmal
bone cyst. Three tumours were composed of cellular
areas only, while the remaining nine cases demon-
strated both cellular and matrix-rich areas. The cellular
areas were made up of polygonal cells with often-
eccentric nuclei, sometimes binucleated, with coarse
chromatin and eosinophilic cytoplasm. Rare spindle
or stellate cells were present. Mitoses were recognized
Table 2. Clinicopathological data for the chondroblastomas
used in the study
Case No Gender Age (years) Bone ABC
1 M 20 Tibia No
2 F 30 Humerus No
3 M 15 Humerus No
4 M 18 Tibia Yes
5 M 14 Tibia No
6 F 12 Humerus No
7 M 27 Os ischii No
8 M 11 Femur No
9 M 12 Femur No
10 M 16 Femur Yes
11 M 12 Tibia No
12 F 17 Humerus No
ABC = aneurysmal bone cyst; f = female; m = male.
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mainly in the cellular areas (Figure 1A). The matrix-
rich areas consisted of fibrous, chondroid or osteoid
areas in which spindle cells, polygonal or osteoblast
like cells were recognized respectively (Figure 1B).
Scant matrix calcification was seen in some cases.
Mature hyaline cartilage was clearly recognized in one
case (case 11). The extent of the matrix-rich area (9
of 12 cases: 75%) was generally less than 50% of
the surface area (66.6% of cases). Chondroid matrix
alone was present in two cases (22.2%); chondroid
and osteoid together in three cases (25%); osteoid
and fibrous in two cases (22.2%); and chondroid,
osteoid, and fibrous in one case (11.1%). Multinucle-
ate giant cells were dispersed throughout the tumour,
especially at the interface between matrix-rich and
cellular areas. Giant cells showed different morpho-
logical features, mainly with regard to shape and the
characteristics of the nuclei. Some showed a more
oval shape and clear nuclei; others were more slen-
der with hyperchromatic or pyknotic nuclei and more
intensely eosinophilic cytoplasm, resembling apoptotic
cells (Figures 1B and 1C). Size was quite homoge-
neous except in one case (case 6), where larger cells,
with numerous nuclei, resembling osteoclasts, were
present. Associated ABC was present in two cases
(16.7%); haemorrhagic areas were present in most of
the cases.
Immunohistochemical evaluation
The data documented below are summarized in
Table 3.
FGF-2
The cellular areas were considered positive in eight
cases (66.6%). The mean sum score of all cases
Table 3. Semi-quantitative scoring results specified for cellular
or matrix-rich areas
Cellular area Matrix-rich area
Antigen Pos % MSS Pos % MSS
FGF-2 8/12 66.6 3.7 6/9 66.6 4.1
FGFR-1 12/12 100 6.9 9/9 100 6
FGFR-3 11/12 91.7 5.4 7/9 77.8 4.7
p21 12/12 100 5.3 9/9 100 3.9
PTHrP 12/12 100 6.3 8/9 88.9 5.6
PTHR1 9/12 75 4.5 3/9 33.3 3.4
bcl-2 6/12 50 3.8 2/9 22.2 2.9
% = percentage of positive cases according to the set cut-off;
MSS = mean sum score.
(negative and positive according to the previously
mentioned cut-off) was 3.7 ± 2.6 SD. Positivity of
the tumour cells was both nuclear and cytoplasmic.
Matrix rich-areas (66.6%) were considered positive in
six cases, the mean sum score being 4.1 ± 2.6 SD.
Positivity was also both nuclear and cytoplasmic.
Giant cells were generally negative (Figure 1D) except
for focal weak positivity in two cases and weak diffuse
positivity in one case. The staining pattern in the giant
cells was cytoplasmic.
FGFR-1
The tumour cells in all cases, in both cellular and
matrix-rich areas, were considered positive, with mean
sum scores of 6.9 ± 0.3 SD for the cellular and 6 ±
1.1 SD for the matrix-rich areas. Positivity was both
nuclear and cytoplasmic.
Giant cells were mostly positive, the intensity and
the distribution being mainly diffuse and strong. Inter-
estingly, completely negative cells were found close to
very strongly staining cells (Figure 1E). The staining
pattern was cytoplasmic. Nearby osteoclasts showed a
more homogeneous staining pattern.
FGFR-3
Tumour cells in both the cellular areas and the
matrix-rich areas demonstrated cytoplasmic positivity
in 91.7% of cases, with mean sum scores of 5.4 ±
1.2 SD for the cellular (91.7%) and 4.7 ± 1.2 SD
(77.8%) for the matrix-rich areas. In all cases except
one, giant cells were positive, often showing weak dif-
fuse positivity. The staining pattern was cytoplasmic
(Figure 1G).
bcl-2
Positive staining of tumour cells was found in the
cellular areas in six cases (50%), with a mean sum
score of 3.8 ± 1.5 SD. Positivity was cytoplasmic. In
the matrix rich-areas, positive staining was found in
two cases (22.2%), with a mean sum score of 2.9 ± 1.4
SD. Positivity was cytoplasmic (Figure 1F). Giant
cells always demonstrated cytoplasmic positivity: the
intensity was weak and the distribution diffuse in six
cases (50%).
p21
In all cases, tumour cells in both the cellular and
the matrix-rich areas were positive, with mean sum
scores of 5.2 ± 1.3 SD for the cellular and 3.9 ± 1.1
Figure 1. (A) Polygonal cells with some mitosis (arrows) are recognized in the cellular areas of chondroblastoma. (B) Matrix-rich
area (M) with obvious cartilage-like cell spaces. Two different types of giant cell are recognized in the cellular areas (C): those with
clear nuclei (squares) and slender cells with hyperchromatic nuclei (arrow-heads ). (C) Osteoclast-like giant cells with numerous
clear nuclei are present. (D) FGF-2 staining is diffuse and intense in the cellular areas, whilst admixed giant cells are completely
negative. (E) FGFR-1 immunostain: positive () and negative () giant cells are found in the same field, while the cellular areas
show diffuse positivity. (F–H) Different levels of expression between matrix-rich (M) and cellular areas (C) for bcl-2, FGFR-3 and
PTHR1, respectively
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SD for the matrix-rich areas. Positivity was nuclear.
Giant cells were always positive, the intensity and
the distribution being predominantly focal (11 cases =
91.6%). The staining pattern was nuclear. Positivity in
the nearby osteoclasts was hardly found.
PTHrP
In the cellular areas, positive cytoplasmic staining
was found in tumour cells in all cases, with a mean
sum score of 6.3 ± 0.5 SD. In the matrix-rich areas,
positive cytoplasmic staining was found in eight cases
(88.9%), with a mean sum score of 5.6 ± 1.6 SD.
Giant cells were always positive, the intensity being
moderate and the distribution diffuse in nine cases
(75%). The staining pattern was cytoplasmic.
PTHR1
In the cellular areas, positive nuclear staining of
tumour cells was found in nine cases (75%), with a
mean sum score of 4.5 ± 1.5 SD. In the matrix-rich
areas, positive cells were found in three cases (33.3%),
with a mean sum score of 3.4 ± 1.3 SD. Positivity was
nuclear and cytoplasmic (Figure 1H).
Giant cells were always positive, except in one case,
and the intensity was weak and the distribution diffuse
in six cases (50%). The staining pattern was nuclear.
Giant cells
Despite the fact that a diffuse or focal staining pattern
was recognized in intra-tumoural giant cells, the distri-
bution of staining was inhomogeneous in most cases,
with positive cells close to completely negative ones;
this was most obvious for FGFR-1. The distribution
of the staining pattern was not related to the differ-
ent morphological features previously described. The
nearby osteoclasts showed more homogeneous stain-
ing.
Statistical analysis
Possible correlations between different amounts of
matrix and types of matrix and different levels of
expression of the proteins studied, and among dif-
ferent molecules in cellular and matrix areas, were
investigated. Although the results did not reach statis-
tical significance, a general trend can be outlined: both
the percentage of positivity and the mean sum scores
were higher in the cellular areas than in the matrix-rich
areas, with the exception of FGF-2, where the percent-
age of positive cases was the same while a higher mean
sum score was found in the matrix-rich areas. In partic-
ular, the difference between the percentages of positive
cases (cellular versus matrix-rich areas) ranged from
0 to 42.7, being the most striking for the expression
of PTHR1, bcl-2, and FGFR-3; while the difference
between the mean sum scores ranged between 1.4 and
0.7, being the most striking for p21 and again PTHR1
and bcl-2. Low SD values were found (range 0.3–1.6),
except for FGF-2.
Discussion
Chondroblastoma is a benign neoplasm with interest-
ing clinical features in terms of site of occurrence and
age at presentation. In the long bones, chondroblas-
toma mainly affects the epiphyses, while at other sites
the lesion arises close to ossification centres. Chon-
droblastoma rarely affects bones that develop through
intra-membranous ossification; hence, there is a close
relationship with the presence of growth plate carti-
lage. Furthermore, the age of presentation is almost
always before fusion of the growth plate. Males, in
which this process is delayed compared with women,
are more often affected.
In the context of these interactions, our analy-
ses confirm the active role of cartilage signalling
molecules in this neoplasm. For all of these proteins,
there was a trend towards more extensive and intense
expression in the cellular areas in comparison with the
matrix-rich areas. The cellular areas are also the areas
in which higher numbers of mitoses are found and
hence they are more active in terms of proliferation.
If we make a comparison with the chondrocytes in
the growth plate, the cellular areas are most similar to
the resting/proliferative zone and the matrix-rich areas
to the transition/hypertrophic zone. From this perspec-
tive, the more extensive and more intense expression
of the growth regulating molecules within the cellular
areas reflects the prevalent expression in the prolifera-
tive zone. We compared the data from both matrix-rich
and cellular areas of the chondroblastomas with our
previously published data on osteochondromas, sec-
ondary peripheral chondrosarcomas, and conventional
central chondrosarcomas [4]. The generally diffuse and
intense expression in chrondroblastomas is more sim-
ilar to chondrosarcomas than to osteochondromas, in
which IHh/PTHrP and FGF signalling molecules are
mostly absent [4]. This is explained by inactivation
of the EXT proteins, as is the case in osteochon-
dromas, which leads to altered expression of heparan
sulphate proteoglycans (HSPG) affecting IHh diffu-
sion and high affinity binding of FGF to its receptors
[4,14–17] In chondrosarcomas, the re-expression of
factors involved in cartilage growth and differentia-
tion is responsible for proliferation and cell survival
[4]. In chondroblastoma, the expression of growth
plate signalling molecules may be due to the pre-
pubertal signalling network, as well as to an implicit
link with cartilage growth itself. Sex hormones are
likely to be involved in this process, given the close
relationship of chondroblastoma to the growth plate
and its occurrence before growth plate fusion. A role
for sex hormones in the pubertal growth spurt and
fusion of the epiphyses is largely accepted. Hence,
both osteochondroma and chondroblastoma are benign
bone tumours, both of which are anatomically closely
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related to the growth plate. However, while IHh/FGF
signalling is absent in the former because of the
impaired expression of HPSG, caused by EXT muta-
tions, this signalling is active in the latter. In fact,
no chondroblastomas were described in patients with
EXT mutations [18]. IHh/FGF signalling is present
in both chondrosarcoma and chondroblastoma; while
the former is a malignant bone tumour, generally with
a low proliferation rate, in which this signalling is
responsible for cell survival [4], the latter is a benign
bone tumour and its high proliferation rate may be
the result of the activation caused by the signalling
molecules. A multi-step genetic model has been postu-
lated for osteochondroma and peripheral chondrosar-
coma [19] but, to date, there is no clear molecular
understanding of the tumourigenesis of chondroblas-
toma. For example, cytogenetic studies have shown no
specific chromosomal alterations [20].
According to the WHO 2002 definition, chondrob-
lastoma is ‘a benign, cartilage-producing neoplasm
usually arising in the epiphyses of skeletally imma-
ture patients’ [2]. However, the nature of the matrix
produced by this tumour cannot simply be viewed as
cartilage, since clear mature cartilage is seldom rec-
ognizable. Moreover, the definition does not account
for the extremely heterogeneous nature of the tumour.
The tumours show variable features, predominantly in
terms of the amount and quality of the extracellular
matrix. Furthermore, different features can be recog-
nized within the same tumour, involving the morphol-
ogy of the cells, determined by the nature of the nearby
matrix. So far, the evidence for the chondroid nature of
this neoplasm is the morphological and ultrastructural
resemblance of the main neoplastic cells to so-called
chondroblasts, the scant positivity of neoplastic cells
for S-100 [21,22], and the presence of proteoglycans in
the extracellular matrix [23,24]. However, the presence
of extracellular matrix closely resembling osteoid, the
immunohistochemical positivity for collagen I, and the
non-specific nature of S-100 immunoreactivity argue
against a true chondroid nature. Two different studies
have approached the problem of chondroid differen-
tiation using the extracellular matrix expression pro-
file [23,25]. Collagen II expression is considered to
be the most specific marker for chondrocytes with a
mature phenotype. Both groups looked for immunohis-
tochemical positivity, achieving different results: Edel
et al found positive expression [25], while Aigner et al
demonstrated absence of collagen II [23], as confirmed
at the mRNA expression level using in situ hybridiza-
tion for isoform collagen II alpha 1A, the splice vari-
ant present in the early precursors of chondrocytes.
From our results, chondroblastoma is a matrix-forming
tumour composed of mesenchymal cells recapitulating
normal chondrogenesis, at least in terms of growth
plate signalling molecule expression. In view of these
features, we favour the hypothesis that this neoplasm
is cartilaginous in type. The production of osteoid and
the positivity for collagen I could be the result of a
process of transdifferentiation of chondrocytes towards
osteoblasts, as has been demonstrated in the chicken
embryo [26], and is postulated to be the case for some
neoplastic lesions [27].
Definitive statements concerning the cartilaginous
or osseous nature of this neoplasm are not possible,
in part because of the static approach offered in the
literature. Attention is paid to the expression of extra-
cellular matrix proteins, providing information about
the presence or absence of a particular protein, in order
to characterize the nature of the nearby cells. This kind
of approach does not account for the extreme plasticity
of mesenchymal cells, as they are able to modify their
shape, function, and pattern of expression, through
processes that have been termed ‘dedifferentiation and
transdifferentiation’, according to the microenviron-
ment that they are set into [28,29]. Experimental mod-
els are needed to understand further the ability of
neoplastic cells to undergo transdifferentiation.
We observed two different populations of giant
cells. One is probably reactive and has morpho-
logical features and immunoreactivity similar to the
nearby osteoclasts. This is in agreement with pre-
vious studies that reported that histochemical and
immunohistochemical markers of osteoclasts were
present in the giant cells of chondroblastoma [30].
Furthermore, recent publications report the presence
of RANK-ligand expression in the chondroblast-
like cells of chondroblastoma [31]. This molecule,
known to be expressed on the membranes of pre-
osteoblastic/stromal cells, binds to its receptor RANK
present on cells of the osteoclastic lineage [32]; hence,
its expression in chondroblastoma suggests an active
role for neoplastic cells in osteoclastogenesis.
The non-homogeneous staining pattern that we
found could reflect differences in the nature of the
giant cells, some being reactive and others being neo-
plastic. Alternatively, the different level of protein
expression could simply be the result of a different
functional status. Noteworthy was the expression of
p21, which was barely found in the nearby osteoclasts.
This is partly explained by the expression of FGFR-
3, which acts upstream of this cell-cycle inhibitor
[5–7]. However, both PTHR1 and bcl-2 are diffusely
expressed in the giant cells, the latter being involved
in anti-apoptotic processes. In chondrocytes, these two
molecules are interrelated by a downstream pathway
leading to increasing proliferation [33]. Hence, in
intra-tumoural giant cells, both anti-apoptotic and cell
cycle-inhibiting proteins are expressed, possibly as a
result of a delicate feedback loop.
In conclusion, chondroblastoma is characterized
by different amounts of cellular and matrix-rich
areas. Both proliferative activity and signalling pro-
tein expression are greater in the cellular than in
the matrix-rich areas, which are analogous to the
proliferating/pre-hypertrophic zone and the hyper-
trophic/calcifying zone of the growth plate, respec-
tively. According to our data, both IHh/PTHrP and
FGF signalling are active in chondroblastoma. The
morphological features and immunophenotype indicate
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the presence of different types of intra-tumoural giant
cells in the same tumour. Taken together, the features
evaluated in this study indicate that chondroblastoma
is a neoplasm originating from a mesenchymal cell
committed towards chondrogenesis via active growth-
plate signalling pathways.
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